Umoja Biopharma

Executive Summary

Umoja Biopharma is a clinical-stage biotechnology company pioneering in vivo CAR T cell therapies through its proprietary VivoVec platform. Headquartered in Seattle, the company was founded in 2019 with a mission to overcome the logistical and manufacturing hurdles of traditional ex vivo CAR T treatments by generating CAR T cells directly inside patients. This approach aims to simplify administration, reduce costs, and broaden accessibility to potentially curative immunotherapies for cancer and autoimmune diseases. Umoja's lead candidate, UB-VV100, targets CD19-positive hematologic malignancies and is currently in Phase 1 clinical trials. The company also has a strategic partnership with AbbVie, which provides financial support and validation for its platform technology.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Data for UB-VV100 in Hematologic Malignancies50% success
• Q4 2026IND Filing for Autoimmune Indication70% success
• TBDMilestone Payment from AbbVie Partnership80% success